COVID-19, SARS-CoV-2 Infection
Conditions
Keywords
COVID-19; SARS-CoV2 infection
Brief summary
This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.
Detailed description
The goal of the study is to to acquire 18F-αvβ6-BP PET/CT images in patients diagnosed with SARS CoV2 and to demonstrate the ability of 18F-αvβ6-BP to detect lung damage.
Interventions
DRUG18F-αvβ6-BP
Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
Sponsors
University of California, Davis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women age ≥ 18 yrs * Diagnosed with SARS CoV2 * Must have 2 sequential COVID negative tests prior to each scan * Must have no previous lung disease prior to SARS CoV2 infection * Lung image (Xray or CT) taken during infectious/ diagnosis period * Will sign the IRB-approved consent form * Able to remain motionless for up to 30-60 minutes per scan.
Exclusion criteria
* Life expectancy \<3 mo * Women who are pregnant or breast-feeding * Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs) * Lack of availability for follow-up assessments * Re-infection with SARS CoV2 between scan sessions * Other active infectious respiratory illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Administration of 18F-αvβ6-BP | baseline | Completion of administration of 18F-αvβ6-BP in SARC CoV2 patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine whether 18F-αvβ6-BP demonstrates accumulation in lung damage | baseline | Uptake of 18F-αvβ6-BP in lung damage will be measured by PET |
Countries
United States
Outcome results
None listed